SenesTech Inc. (NASDAQ:SNES) is in the transition from being a drug discovery company to commercialization of its rodenticide contraceptive, ContraPest. The replacement of second generation anti-coagulant products with alternative treatments would open a multimillion dollar market in the reduction in rat populations alone. Possible penetration into mouse control would be a significant increase in the total available market for SNES.
Zacks Small-Cap Research is initiating coverage of SenesTech with a price target of $1.35 a share.
SenesTech produces a contraceptive system, ContraPest, that is effective on both black and brown rats. By rendering both male and female rats unable to produce young, reproduction ends, and the rats live out a normal life span without giving birth.
The product is approved for use by the EPA and has received registration in all 50 states.
The company has deployments in Washington D.C.; St Louis; San Francisco Bay Area; Southern California transit agency as well as poultry farms, a winery and an egg facility. Other deployments include animal sanctuaries and 11 zoos.
Potential extensions to other pests could double the total available market.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.